RecruitingNCT07776522
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
PHASE2 · 50 planned enrolment
- Countries listed
- 1
- Registry update
- August 20, 2026
immortal.lifeTrial registrations containing the exact intervention label Aflibercept (2.0 mg).
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 50 planned enrolment
PHASE1 · 12 planned enrolment